Genes associated with lysosomal dysfunction increase the risk of Parkinson’s disease (PD), according to a study led by ...

The Abu Dhabi health care company M42 is to make an investment in biotech longevity specialist Juvenescence as a route to moving into drug discovery and development, with the two forming a partnership ...

Radnet Inc. expanded its commitment to the use of AI in improving diagnosis of breast cancer with an all-stock purchase of Icad Inc. for approximately $103 million. The transaction is expected to ...

In a blast from the past, U.S. President Donald Trump signed an executive order April 15 to deliver on his 2016 campaign promises and strengthen or reinstate efforts of his first administration to ...

The Abu Dhabi health care company M42 is to make an investment in U.K.-based longevity specialist Juvenescence as a route to moving into drug discovery and development, with the two forming a ...

Neuranics Ltd. recently raised $8 million in seed funding which is “extremely important” for the company as it looks to scale its magnetic sensing technology, which detects muscle activity without ...

Co. Ltd. has announced IND clearances by the FDA for its XS-411 and XS-228 cell therapies, for Parkinson’s disease and amyotrophic lateral sclerosis (ALS), respectively.

After more than three years of discussion, the World Health Organization’s Intergovernmental Negotiating Body (INB) has agreed on a proposal to prevent, prepare and respond to a pandemic. The plan is ...

Researchers at Provincial Health Services Authority and University of British Columbia have synthesized radiolabeled peptides targeting gastrin-releasing peptide receptor (GRPR) reported to be useful ...

Stem cell implantation is a step closer to becoming the next strategy against Parkinson's disease. Two clinical trials, one in phase I and the other in phase I/II, have demonstrated their safety and ...

Researchers from Eli Lilly & Co. reported preclinical data on LY-3954068, a MAPT small-interference RNA (siRNA) strategy in AD models. The therapy is designed to reduce tau protein synthesis by ...

Biohaven Pharmaceuticals Inc. has presented preclinical data on their novel bispecific degrader BHV-1310 for the potential treatment of autoimmune disorders. To date, about 10% of the global ...